CA2208018C - Sulfonamides - Google Patents

Sulfonamides Download PDF

Info

Publication number
CA2208018C
CA2208018C CA002208018A CA2208018A CA2208018C CA 2208018 C CA2208018 C CA 2208018C CA 002208018 A CA002208018 A CA 002208018A CA 2208018 A CA2208018 A CA 2208018A CA 2208018 C CA2208018 C CA 2208018C
Authority
CA
Canada
Prior art keywords
pyridin
methoxy
phenoxy
pyrimidin
ethoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CA002208018A
Other languages
English (en)
French (fr)
Other versions
CA2208018A1 (en
Inventor
Volker Breu
Kaspar Burri
Jean-Marie Cassal
Martine Clozel
Georges Hirth
Bernd-Michael Loffler
Marcel Muller
Werner Neidhart
Henri Ramuz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of CA2208018A1 publication Critical patent/CA2208018A1/en
Application granted granted Critical
Publication of CA2208018C publication Critical patent/CA2208018C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/69—Benzenesulfonamido-pyrimidines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cardiology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Bipolar Transistors (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Surgical Instruments (AREA)
  • Lubricants (AREA)
  • Steroid Compounds (AREA)
CA002208018A 1994-12-20 1995-12-08 Sulfonamides Expired - Lifetime CA2208018C (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CH3837/94-6 1994-12-20
CH383794 1994-12-20
CH2419/95-1 1995-08-24
CH241995 1995-08-24
PCT/EP1995/004843 WO1996019459A1 (en) 1994-12-20 1995-12-08 Novel sulfonamides

Publications (2)

Publication Number Publication Date
CA2208018A1 CA2208018A1 (en) 1996-06-27
CA2208018C true CA2208018C (en) 2007-03-27

Family

ID=25690401

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002208018A Expired - Lifetime CA2208018C (en) 1994-12-20 1995-12-08 Sulfonamides

Country Status (25)

Country Link
US (1) US6004965A (OSRAM)
EP (1) EP0799209B1 (OSRAM)
JP (1) JP2989014B2 (OSRAM)
KR (1) KR100445085B1 (OSRAM)
CN (1) CN1098254C (OSRAM)
AT (1) ATE246681T1 (OSRAM)
AU (1) AU701767B2 (OSRAM)
BR (1) BR9510104A (OSRAM)
CA (1) CA2208018C (OSRAM)
CY (1) CY2495B1 (OSRAM)
CZ (1) CZ287916B6 (OSRAM)
DE (1) DE69531457T2 (OSRAM)
DK (1) DK0799209T3 (OSRAM)
ES (1) ES2203649T3 (OSRAM)
FI (1) FI120397B (OSRAM)
HU (1) HU228619B1 (OSRAM)
IL (1) IL116385A (OSRAM)
MA (1) MA23744A1 (OSRAM)
MY (1) MY131126A (OSRAM)
NO (1) NO316645B1 (OSRAM)
NZ (1) NZ297797A (OSRAM)
PT (1) PT799209E (OSRAM)
SA (1) SA95160421B1 (OSRAM)
TW (1) TW313568B (OSRAM)
WO (1) WO1996019459A1 (OSRAM)

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6063911A (en) * 1993-12-01 2000-05-16 Marine Polymer Technologies, Inc. Methods and compositions for treatment of cell proliferative disorders
TW555765B (en) 1996-07-09 2003-10-01 Amgen Inc Low molecular weight soluble tumor necrosis factor type-I and type-II proteins
ATE406176T1 (de) 1996-12-06 2008-09-15 Amgen Inc Il-1-inhibitor in kombinationstherapie zur behandlung il-1-vermittelter krankheiten
DK0897914T3 (da) 1997-08-19 2004-09-27 Hoffmann La Roche Fremgangsmåde til fremstilling af 2,5-disubstituerede pyridiner
US7329670B1 (en) 1997-12-22 2008-02-12 Bayer Pharmaceuticals Corporation Inhibition of RAF kinase using aryl and heteroaryl substituted heterocyclic ureas
US7517880B2 (en) 1997-12-22 2009-04-14 Bayer Pharmaceuticals Corporation Inhibition of p38 kinase using symmetrical and unsymmetrical diphenyl ureas
DK0979822T3 (da) * 1998-08-10 2006-03-27 Hoffmann La Roche Fremgangsmåde til fremstilling af 2-carbamoyl-pyridiner
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
RU2319693C9 (ru) 1999-01-13 2008-08-20 Байер Копэрейшн Производные мочевины (варианты), фармацевтическая композиция (варианты) и способ лечения заболевания, связанного с ростом раковых клеток (варианты)
US7928239B2 (en) 1999-01-13 2011-04-19 Bayer Healthcare Llc Inhibition of RAF kinase using quinolyl, isoquinolyl or pyridyl ureas
CA2359244C (en) 1999-01-13 2013-10-08 Bayer Corporation .omega.-carboxy aryl substituted diphenyl ureas as p38 kinase inhibitors
WO2000042012A1 (en) * 1999-01-13 2000-07-20 Bayer Corporation φ-CARBOXYARYL SUBSTITUTED DIPHENYL UREAS AS RAF KINASE INHIBITORS
US8124630B2 (en) 1999-01-13 2012-02-28 Bayer Healthcare Llc ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
TWI284642B (en) * 1999-01-18 2007-08-01 Hoffmann La Roche Novel heterocyclic sulfonamides
US6417360B1 (en) * 1999-03-03 2002-07-09 Hoffmann-La Roche Inc. Heterocyclic sulfonamides
ZA200002318B (en) * 1999-05-22 2000-11-16 Actelion Pharmaceuticals Ltd Aqueous pharmaceutical composition.
AU747596B2 (en) * 1999-05-22 2002-05-16 Actelion Pharmaceuticals Ltd Aqueous pharmaceutical composition
CA2315614C (en) 1999-07-29 2004-11-02 Pfizer Inc. Pyrazoles
AU775194B2 (en) * 1999-09-03 2004-07-22 Actelion Pharmaceuticals Ltd Bis-sulfonamides
MXPA02006250A (es) * 1999-12-22 2004-09-06 Actelion Pharmaceuticals Ltd Derivados de butino diol.
AU2001265871A1 (en) * 2000-04-25 2001-11-07 Actelion Pharmaceuticals Ltd Substituted sulfonylaminopyrimidines
US6387915B2 (en) 2000-05-31 2002-05-14 Pfizer Inc. Isoxazole-sulfonamide endothelin antagonists
US6670362B2 (en) 2000-09-20 2003-12-30 Pfizer Inc. Pyridazine endothelin antagonists
US8168616B1 (en) 2000-11-17 2012-05-01 Novartis Ag Combination comprising a renin inhibitor and an angiotensin receptor inhibitor for hypertension
MXPA03004780A (es) 2000-12-18 2004-05-21 Actelion Pharmaceuticals Ltd Nuevas sulfamidas.
US7235576B1 (en) 2001-01-12 2007-06-26 Bayer Pharmaceuticals Corporation Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
WO2002083650A1 (en) * 2001-04-11 2002-10-24 Actelion Pharmaceuticals Ltd Novel sulfonylamino-pyrimidines
US7371763B2 (en) 2001-04-20 2008-05-13 Bayer Pharmaceuticals Corporation Inhibition of raf kinase using quinolyl, isoquinolyl or pyridyl ureas
PT1580188E (pt) 2002-02-11 2012-01-25 Bayer Healthcare Llc Aril-ureias como inibidores de cinases
WO2003068228A1 (en) 2002-02-11 2003-08-21 Bayer Pharmaceuticals Corporation Aryl ureas with angiogenesis inhibiting activity
WO2003068229A1 (en) 2002-02-11 2003-08-21 Bayer Pharmaceuticals Corporation Pyridine, quinoline, and isoquinoline n-oxides as kinase inhibitors
US20040002451A1 (en) 2002-06-20 2004-01-01 Bruce Kerwin Compositions of pegylated soluble tumor necrosis factor receptors and methods of preparing
CA2507334C (en) * 2002-12-02 2013-05-07 Actelion Pharmaceuticals Ltd. Pyrimidine-sulfamides and their use as endothelian receptor antagonist
US7557129B2 (en) 2003-02-28 2009-07-07 Bayer Healthcare Llc Cyanopyridine derivatives useful in the treatment of cancer and other disorders
ATE366108T1 (de) 2003-05-20 2007-07-15 Bayer Pharmaceuticals Corp Diaryl-harnstoffe für durch pdgfr vermittelte krankheiten
DK1663978T3 (da) 2003-07-23 2008-04-07 Bayer Pharmaceuticals Corp Fluorsubstitueret omega-carboxyaryl-diphenylurinstof til behandling og forebyggelse af sygdomme og lidelser
GB0327839D0 (en) 2003-12-01 2003-12-31 Novartis Ag Organic compounds
CA2558020A1 (en) 2004-03-17 2005-09-29 Novartis Ag Use of renin inhibitors in therapy
TW200628467A (en) 2004-11-11 2006-08-16 Actelion Pharmaceuticals Ltd Novel sulfamides
US7402730B1 (en) 2005-02-03 2008-07-22 Lexicon Pharmaceuticals, Inc. Knockout animals manifesting hyperlipidemia
GT200600381A (es) 2005-08-25 2007-03-28 Compuestos organicos
AU2007276433B2 (en) 2006-07-20 2011-06-16 Novartis Ag Amino-piperidine derivatives as CETP inhibitors
AR062501A1 (es) 2006-08-29 2008-11-12 Actelion Pharmaceuticals Ltd Composiciones terapeuticas
HUE033960T2 (en) 2006-12-08 2018-01-29 Lexicon Pharmaceuticals Inc Monoclonal Antibodies to ANGPTL3
US8871247B2 (en) 2007-02-19 2014-10-28 Marine Polymer Technologies, Inc. Hemostatic compositions and therapeutic regimens
MX2010001837A (es) 2007-08-17 2010-03-10 Actelion Pharmaceuticals Ltd Derivados de 4-pirimidinasulfamida.
FR2921062A1 (fr) * 2007-09-17 2009-03-20 Commissariat Energie Atomique Composes utiles comme ligands et notamment comme chromophores organiques de complexation des lanthanides et leurs applications
AR069165A1 (es) 2007-11-05 2010-01-06 Novartis Ag Derivados de 4-bencilamino-1-carboxacilpiperidina como inhibidores de cetp utiles para el tratamiento de hiperlipidemia
PL2404901T3 (pl) 2007-12-03 2013-10-31 Novartis Ag 1,2-Dipodstawione pochodne 4-benzyloamino-pirolidyny jako inhibitory CETP użyteczne do leczenia chorób, takich jak hiperlipidemia lub stwardnienie tętnic
EA201101621A1 (ru) 2009-05-15 2012-05-30 Новартис Аг Производные бензоксазолона в качестве ингибиторов альдостеронсинтазы
PE20120403A1 (es) 2009-05-15 2012-05-03 Novartis Ag Aril-piridinas como inhibidoras de sintasa de aldosterona
CN102448928B (zh) 2009-05-28 2014-10-01 诺华股份有限公司 作为中性溶酶(neprilysin)抑制剂的取代的氨基丁酸衍生物
EP2594557B1 (en) 2009-05-28 2016-08-10 Novartis AG Substituted aminopropionic derivatives as neprilysin inhibitors
CN102712589B (zh) 2009-11-17 2015-05-13 诺华股份有限公司 作为醛固酮合酶抑制剂的芳基-吡啶衍生物
JO2967B1 (en) 2009-11-20 2016-03-15 نوفارتس ايه جي Acetic acid derivatives of carbamoyl methyl amino are substituted as new NEP inhibitors
EP2507234B1 (en) 2009-11-30 2014-03-12 Novartis AG Imidazole derivatives as aldosterone synthase inhibitors
JP2013523898A (ja) 2010-04-15 2013-06-17 マリン ポリマー テクノロジーズ，インコーポレーテッド ポリ−ｎ−アセチルグルコサミンナノファイバーの抗菌性の適用
US8673974B2 (en) 2010-11-16 2014-03-18 Novartis Ag Substituted amino bisphenyl pentanoic acid derivatives as NEP inhibitors
US8877815B2 (en) 2010-11-16 2014-11-04 Novartis Ag Substituted carbamoylcycloalkyl acetic acid derivatives as NEP
HUE043576T2 (hu) 2010-11-24 2019-08-28 Lexicon Pharmaceuticals Inc Antitestek notum pektinacetilészterázhoz
AU2012242479B2 (en) 2011-04-15 2015-04-16 Marine Polymer Technologies, Inc. Treatment of disease with poly-n-acetylglucosamine nanofibers
UY35144A (es) 2012-11-20 2014-06-30 Novartis Ag Miméticos lineales sintéticos de apelina para el tratamiento de insuficiencia cardiaca
US9383357B2 (en) 2012-12-07 2016-07-05 Northwestern University Biomarker for replicative senescence
EP2956464B1 (en) 2013-02-14 2018-03-28 Novartis AG Substituted bisphenyl butanoic phosphonic acid derivatives as nep (neutral endopeptidase) inhibitors
HK1218298A1 (zh) 2013-07-25 2017-02-10 Novartis Ag 用於治疗心力衰竭的环状多肽
UY35671A (es) 2013-07-25 2015-02-27 Novartis Ag Bioconjugados de polipéptidos de apelina sintética
CN107406490A (zh) 2015-01-23 2017-11-28 诺华股份有限公司 具有改善的半衰期的合成apelin脂肪酸缀合物
UY38072A (es) 2018-02-07 2019-10-01 Novartis Ag Compuestos derivados de éster butanoico sustituido con bisfenilo como inhibidores de nep, composiciones y combinaciones de los mismos
TWI835843B (zh) 2018-10-03 2024-03-21 瑞士商亨斯邁紡織染化（瑞士）有限公司 新的經吡啶及經嘧啶取代之三ｕｖ吸收劑
US20230373967A1 (en) 2020-11-05 2023-11-23 Idorsia Pharmaceuticals Ltd A stable crystalline hydrate of clazosentan disodium salt
KR20240121242A (ko) 2021-12-17 2024-08-08 넥세라 파마 씨오., 엘티디. 클라조센탄 디소듐 염, 이의 제조 및 이를 포함하는 약학 조성물
WO2025151724A1 (en) * 2024-01-12 2025-07-17 Rectify Pharmaceuticals, Inc. Pyridinyloxypyridines as modulators of atp -binding cassette transporters and their use in treating medical conditions

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW270116B (OSRAM) * 1991-04-25 1996-02-11 Hoffmann La Roche
RU2086544C1 (ru) * 1991-06-13 1997-08-10 Хоффманн-Ля Рош АГ Бензолсульфонамидные производные пиримидина или их соли, фармацевтическая композиция для лечения заболеваний, связанных с активностью эндотелина
TW287160B (OSRAM) * 1992-12-10 1996-10-01 Hoffmann La Roche
TW394761B (en) * 1993-06-28 2000-06-21 Hoffmann La Roche Novel Sulfonylamino Pyrimidines
IL111959A (en) * 1993-12-17 2000-07-16 Tanabe Seiyaku Co N-(polysubstituted pyrimidin-4-yl) benzenesulfonamide derivatives their preparation and pharmaceutical compositions containing them

Also Published As

Publication number Publication date
CY2495B1 (en) 2005-09-02
HK1001973A1 (en) 1998-07-24
NZ297797A (en) 1999-10-28
ES2203649T3 (es) 2004-04-16
FI972628A0 (fi) 1997-06-18
JP2989014B2 (ja) 1999-12-13
CN1098254C (zh) 2003-01-08
HU228619B1 (en) 2013-04-29
NO316645B1 (no) 2004-03-22
TW313568B (OSRAM) 1997-08-21
BR9510104A (pt) 1997-11-25
FI120397B (fi) 2009-10-15
CA2208018A1 (en) 1996-06-27
PT799209E (pt) 2003-12-31
MA23744A1 (fr) 1996-07-01
ATE246681T1 (de) 2003-08-15
IL116385A0 (en) 1996-03-31
EP0799209A1 (en) 1997-10-08
HUT77884A (hu) 1998-09-28
CZ287916B6 (cs) 2001-03-14
DE69531457D1 (en) 2003-09-11
AU4304196A (en) 1996-07-10
NO972538L (no) 1997-06-04
CN1170407A (zh) 1998-01-14
NO972538D0 (no) 1997-06-04
FI972628L (fi) 1997-06-18
EP0799209B1 (en) 2003-08-06
MY131126A (en) 2007-07-31
JPH10509182A (ja) 1998-09-08
KR100445085B1 (ko) 2004-10-14
WO1996019459A1 (en) 1996-06-27
MX9704587A (es) 1998-07-31
DE69531457T2 (de) 2004-06-24
CZ187497A3 (en) 1997-10-15
US6004965A (en) 1999-12-21
AU701767B2 (en) 1999-02-04
SA95160421B1 (ar) 2006-05-01
IL116385A (en) 2000-07-16
DK0799209T3 (da) 2003-11-24

Similar Documents

Publication Publication Date Title
CA2208018C (en) Sulfonamides
AU678467B2 (en) Novel sulfonylamino pyrimidines
CA2071193C (en) Sulfonamides
KR100819668B1 (ko) 신규한 피리미딘-설퍼아마이드
IL107884A (en) Sulphonamides, their manufacture and pharmaceutical compositions containing them
NZ242396A (en) 6-hydroxyalkoxy-pyrimidin-4-yl benzenesulphonamide derivatives; pharmaceutical compositions and preparatory processes
NZ512662A (en) 4-(Heterocyclylsulfonamido)-5-methoxy-6-(2- methoxyphenoxy)-2-phenyl- or 2-pyridylpyrimidines as endothelin receptor antagonists
AU691353B2 (en) Novel sulfonamides
WO2002024665A1 (en) Arylalkane-sulfonamides having endothelin-antagonist activity
AU2002212171A1 (en) Arylalkane-sulfonamides having endothelin-antagonist activity
CA2187130C (en) Novel sulphonamides
HK1001973B (en) Sulfonamides
RU2151767C1 (ru) Сульфонамиды и фармацевтическая композиция
MXPA97004587A (es) Sulfonamidas novedosas
NO327220B1 (no) Alkansulfonamider, fremgangsmate for fremstilling av slike, disse forbindelsene for anvendelse som medikamenter for behandling av lidelser samt anvendelse for fremstilling av medikamenter for behandling av lidelser
KR100521950B1 (ko) 설포닐아미노피리미딘
EP1322624A1 (en) Arylalkane-sulfonamides having endothelin-antagonist activity

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry

Effective date: 20151208